Best Sarcoma Doctors in Hyderabad — CION's Dedicated Soft Tissue Sarcoma Panel

The best doctor for soft tissue sarcoma is a surgical oncologist trained in wide local excision and limb-sparing surgery, paired with a medical oncologist current with subtype-specific therapy (including imatinib for GIST) and a radiation oncologist for neoadjuvant approaches. At CION, every sarcoma case is reviewed by a multidisciplinary tumour board, with surgical leadership by Dr. Mohammed Imaduddin (M.Ch Surgical Oncology) and medical oncology by Dr. T. Raghavender Reddy (dual MD Rad Onc + DM Med Onc).

Soft tissue sarcoma is not one cancer — it is a group of 70+ subtypes per WHO classification. The most common include: liposarcoma (well-differentiated, dedifferentiated, myxoid, pleomorphic — each behaves differently), leiomyosarcoma (often retroperitoneal or uterine), undifferentiated pleomorphic sarcoma (aggressive, may benefit from chemo), synovial sarcoma (chemo-sensitive), angiosarcoma, malignant peripheral nerve sheath tumour (MPNST), and gastrointestinal stromal tumour (GIST — distinct, treated with imatinib). Each subtype has different chemo-sensitivity, prognosis, and surgical approach. Specialist pathology review with IHC and molecular markers is essential.

Limb-sparing surgery is the modern default for extremity soft tissue sarcoma — preserving the limb with negative surgical margins while maintaining function. Achieved in 90%+ of extremity STS cases with combined modality treatment (surgery + radiation). The principle is wide local excision with adequate margins of normal tissue (typically 1–2 cm) around the tumour. Neoadjuvant radiation often allows tighter margins safely. Amputation is reserved for cases where limb-sparing is not oncologically safe or functionally reasonable. CION's surgical oncology team prioritises limb-sparing approaches and discusses margins explicitly with each patient.

GIST (gastrointestinal stromal tumour) is technically a soft tissue sarcoma but is treated very differently. It arises from interstitial cells of Cajal in the GI tract — most commonly stomach (60%), small intestine (30%), and rectum/colon. Most GISTs have KIT or PDGFRA mutations, making them sensitive to imatinib (Gleevec) — the original targeted therapy success story. Treatment is: surgical resection + imatinib for KIT-positive intermediate/high-risk disease (3 years adjuvant for some) + sunitinib or regorafenib for imatinib-resistant disease. Mutational testing guides therapy selection. CION's medical oncology team manages GIST patients per current NCCN guidelines.

Neoadjuvant radiation = pre-operative radiation, typically 50 Gy over 5 weeks before wide local excision. Compared to post-operative radiation: it allows smaller radiation fields (since the tumour is still present and defines the target), often produces tighter surgical margins (some tumour shrinkage), and reduces late complications like joint stiffness and lymphedema. The trade-off is slightly higher wound complications during surgery. For most intermediate/high-grade extremity and trunk STS, neoadjuvant radiation is increasingly preferred. CION's radiation oncology team uses neoadjuvant radiation per current sarcoma protocols.

Most patients with soft tissue sarcoma do NOT need chemotherapy. Chemotherapy benefit varies dramatically by subtype, grade, and stage. High-grade synovial sarcoma, undifferentiated pleomorphic sarcoma, myxoid/round cell liposarcoma, and large deep high-grade STS may benefit from doxorubicin + ifosfamide. Most other subtypes do not. For advanced/metastatic disease, doxorubicin-based first-line therapy followed by pazopanib, trabectedin, eribulin, or subtype-specific agents. CION's medical oncology team selects chemotherapy based on evidence per subtype — not as default for all STS.

Pulmonary metastases are the most common site for soft tissue sarcoma spread. For oligometastatic pulmonary disease (1–5 lesions), surgical metastasectomy can provide long-term survival in selected patients. For multiple/diffuse pulmonary metastases, systemic therapy is the approach. CION's multidisciplinary tumour board reviews pulmonary metastasis cases with thoracic surgery input where indicated.

This is unfortunately common — and not your fault. The management is re-excision with wider margins by a sarcoma-experienced surgical oncologist, often combined with radiation. Outcomes are still good if the re-excision is adequate. Do NOT let the original surgeon perform the re-excision unless they specialise in sarcoma — the principles are different. CION's surgical oncology team commonly handles re-excision cases referred from general surgery.

A second opinion is especially valuable for sarcoma — both because pathology subtype classification can vary across pathologists and because surgical and treatment decisions vary across centres. At CION the second opinion is free, written, and yours to keep — our multidisciplinary tumour board reviews your imaging, biopsy/pathology, and existing recommendation and provides a documented opinion you can take anywhere.

Costs vary widely by subtype and treatment intensity. Wide local excision (extremity STS) ranges approximately ₹1,50,000 to ₹4,00,000. Neoadjuvant or adjuvant radiation ₹2,50,000 to ₹5,00,000. Adjuvant chemotherapy (where indicated) ₹2,00,000 to ₹5,00,000. GIST: surgery + imatinib (3 years adjuvant) — imatinib alone can be ₹6,00,000–₹15,00,000+ depending on generic vs brand. Retroperitoneal sarcoma surgery is significantly higher due to complexity. For a detailed cost breakdown, see our sarcoma treatment in Hyderabad page. Every CION patient receives a written, itemised cost estimate. Aarogyasri, EMI, and cashless insurance accepted.

No — this page covers soft tissue sarcomas (liposarcoma, leiomyosarcoma, GIST, synovial sarcoma, UPS, MPNST, angiosarcoma, and others arising from soft tissues). Bone sarcomas (osteosarcoma, Ewing sarcoma, chondrosarcoma) are biologically distinct and treated under different protocols. See our bone cancer doctors in Hyderabad page for that pathway. If you are not sure which type you have, your biopsy report will state it — or ask any CION oncologist to review your report in your free 45-minute consultation.